C61 N40
Conditions
Interventions
Group 1: Study participants with prostate cancer, benign prostatic hyperplasia, after radical prostatectomy and healthy participants undergoing prostate cancer screening are informed in detail about t
Sponsors
Ludwig-Maxilians-Universität München, Fakulät für Physik
Eligibility
Sex/Gender
Male
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Consent was given, participant is older than 18 years, belonging to one of the cohorts examined
Exclusion criteria
Exclusion criteria: The presence of several cancers, cancer treatment within the last two years before inclusion in the study, submission of spontaneous/ exprimate urine samples not possible, non-compliance of the participant
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean and standard deviation of the global molecular fingerprint (GMF). | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Field-resolved spectroscopy of exprimate urine will be technically feasible. 2. There will be variation in GMFs among different healthy individuals (inter-personal variation) and within one individual over time (intra-personal variation). Inter-personal variation will be greater than intra-personal variation and mean differences will be > 0.8 STD (standard deviation). 3. GMFs will be reproducible, i.e. the GMF variation of repeated measurements of the same sample will be smaller than the inter- and intra-personal variation and the mean difference will be > 0.8 STD (standard deviation). 4. There will be differences in GMFs between groups of patients with prostate cancer, benign prostate hyperplasia, participants undergoing cancer screening, patients after radical prostectomy and healthy volunteers. | — |
Countries
Germany
Contacts
Public ContactJacqueline Hermann
Fakultät für Physik, Ludwig-Maximilians-Universität München; Urologische Klinik und Poliklinik, LMU Klinikum
Outcome results
None listed